Q: any comment on earnings should i switch to Well health or Vitalhub
5i Research Answer:
EPS of 1c missed estimates of 14c; revenue of $10.37M missed estimates of $10.5M. EBITDA of $4.1M missed estimates of $5.68M. Sales increased 71% year over year. Product revenue growth was very strong, though margins fell. Its big acquisition in July has closed and looks decent. The stock fell sharply on the quarterly news, and investors are still unhappy about the trial-miss in fungus earlier this year. Growth is expected in 2025, but the stock is pricey based on revenue estimates. We would consider it OK, but would prefer both VHI and WELL today.